Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning
|
PDF
|
Pharma Strategy: Sustainable growth, more patient benefits, and less cost to
society
Bill Anderson, Chief Executive Officer Roche Pharmaceuticals
|
PDF
|
Commercial Opportunities
Teresa Graham, Head of Pharma Global Product Strategy
|
PDF
|
Late Stage Pipeline Oncology & Non-malignant Hematology
Levi Garraway, Chief Medical Officer and Head Global Product Development
|
PDF
|
Late Stage Pipeline Neuroscience
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
|
PDF
|
Late Stage Pipeline Immunology & Ophthalmology
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global
Product Strategy
|
PDF
|
Infectious Disease: A close look at the HBV pipeline
John Young, Global Head of Infectious Diseases, Roche Pharma Research & Early
Development
|
PDF
|
Late Stage Infectious Diseases: Influenza & SARS-CoV-2
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global
Product Strategy
|
PDF
|
Appendix |
Pipeline overview |
PDF
|
Patient populations |
PDF
|